Delivery Order SPE2DB20D1100-SPE2DB25FC6G9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,839.36 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed price contract. The award was issued on August 28, 2025, with an ultimate completion date of August 29, 2025, and represents a non-set-aside competitive procurement. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,888.67 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60 count) on August 19, 2025, with a completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order draws from AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Otezla 30 mg tablets in a 60-count quantity. This competitively awarded, non-set-aside contract has a ceiling value of $23,776.76 and was executed on September 11, 2025, with an ultimate completion date of September 12, 2025. The firm fixed price delivery order represents a single-transaction procurement from...
- The Defense Logistics Agency awarded a delivery order valued at $9,048.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on June 18, 2025, with completion scheduled for June 20, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $19,860.97 delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on June 26, 2025, with completion expected by June 27, 2025. This firm fixed-price contract represents a non-competitive set-aside and reflects AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs. The order is being performed at the contractor's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,299.99 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,386.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,785.70 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed price contract. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. This delivery order represents a non-competitive purchase executed under an existing contract vehicle and will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Otezla 30 mg tablets in a quantity of 60s at a firm fixed price of $2,802.78, with completion scheduled for September 9, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg with a ceiling value of $12,882.51 on August 15, 2025. This competitively awarded, firm fixed-price delivery order is due for completion by August 18, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to meet federal procurement requirements...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FC6G9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $84,204.97 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on June 2, 2025, with an ultimate completion date of June 3, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken, PA 19428. This delivery order is issued under AmerisourceBergen's SPE2DX Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The parent IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. Otezla, an immunosuppressant medication used in the treatment of certain inflammatory conditions, reflects the company's role as a critical pharmaceutical vendor for federal military and veteran healthcare systems. AmerisourceBergen maintains a robust portfolio of federal medical contracts that demonstrate its capability to meet DLA procurement requirements through open competition across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $84.2k | 6/2/25 |